T cells are a key component of the adaptive immune system. Both chimeric antigen receptor (CAR) and T cell receptor (TCR) immunotherapies have been clinically approved to treat various blood cancers. These cells are primarily derived from patient donors and are a valuable and scarce resource. Efficient editing and sustained viability of these cells post-editing remain critical challenges for researchers.

This flyer provides information on how Dr. Manuel Albanese and his team at the Max von Pettenkofer Institute and Gene Center in Munich, Germany, used Synthego’s Synthetic sgRNA to overcome these challenges with editing in primary human resting CD4 T cells.